Predicting onset of COVID-19
BioSymetrics collaborates with Janssen and Sema4 to Predict the Onset of COVID-19
Register for free to listen to this article
Listen with Speechify
0:00
5:00
BioSymetrics, a biomedical artificial intelligence (AI) company that provides clinical insights and helps researchers develop drugs with greater speed and precision, announced recently a collaboration with Sema4, a patient-centered health intelligence company, and Janssen Pharmaceuticals Inc. The collaboration will focus on predicting the onset and severity of COVID-19 among different populations using machine learning.
As part of the collaboration, the parties will use the Contingent-AI engine—a key part of BioSymetrics' overall August system—across several projects to characterize high-risk populations; measure and predict disease progression based on biological risk factors and treatment course; and identify markers for clinical phenotype and severity of disease.
BioSymetrics Augusta product is an advanced SaaS-based biomedical machine learning platform. Augusta applies what the company calls “a first-of-its-kind contingent AI” by combining machine learning and data pre-processing/integration in an iterative framework. The result, the company says, is a “proven increase of speed to market through all stages of drug discovery and research.”
"We've been working on deploying AI in the clinical setting for several years," said Anthony Iacovone, co-founder and chairman of BioSymetrics. "We've demonstrated that machine learning can bring speed and precision to helping identify at risk patient populations, predict disease outcomes, and build better treatments, but the pandemic has now pushed biomedical AI technology to the fore front of innovative necessity."
Added Eric Schadt, founder and CEO of Sema4d: "There is dramatic heterogeneity within the COVID-19 patient groups and a spectrum of disease risk that must be interpreted probabilistically—something of which I believe this collaboration will drive through innovation and combined expertise."
BioSymetrics was founded in 2016 to address the data issues that limit the effectiveness of machine learning for biomedical data with a focus on building practical frameworks for clinical analysis and early stage drug discovery. Their platform uses a patent pending AI iteration framework that can be used in conjunction with clinical research to predict target mechanism, identify lead compounds, or provide clinical insights.
The collaboration will operate across several projects with a goal of enabling a vaccine and course of treatment against SARS-CoV-2.
